Dominant mutations in the gene for •-synuclein, a small presynaptic protein, can cause Parkinson’s disease. Although there is still substantial debate about the precise mechanisms, •-synuclein is toxic to vulnerable neurons, probably as a result of its tendency to aggregate. Opposing this is another gene product that, when mutated, causes a recessive form of parkinsonism, parkin. Parkin has been recently shown to protect cells against •-synuclein toxicity. However, the precise details of the mechanism are unclear. This review will discuss the concept that there are multiple neuronal functions that are targeted by mutant •-synuclein, and in many cases, there is evidence that parkin can protect cells against damage to the same systems. The authors will also discuss ways in which to test some of these ideas, by using newly identified genes such as DJ-1 that cause similar phenotypes.
Get full access to this article
View all access options for this article.
References
1.
Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, and others. 2000. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron25:239–252.
2.
Ahn BH, Rhim H, Kim SY, Sung YM, Lee MY, Choi JY, and others. 2002. Alpha-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem277:12334–42.
3.
Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease. Science295:865–868.
4.
Baptista MJ, O’Farrell C, Daya S, Ahmad R, Miller DW, Hardy J, and others. 2003. Co-ordinate transcriptional regulation of dopamine synthesis genes by alpha-synuclein in human neuroblastoma cell lines. J Neurochem85:957–968.
5.
Beites CL, Xie H, Bowser R, Trimble WS. 1999. The septin CDCrel-1 binds syntaxin and inhibits exocytosis. Nat Neurosci2:434–439.
6.
Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitinproteasome system by protein aggregation. Science292: 1552–5.
7.
Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, and others. 2003. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science299:256–259.
8.
Braak H, Braak E. 2000. Pathoanatomy of Parkinson’s disease. J Neurol247(suppl 2):3–10.
9.
Cabin DE, Shimazu K, Murphy D, Cole NB, Gottschalk W, McIlwain KL, and others. 2002. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci22:8797–8807.
10.
Chung KK, Zhang Y, Lim KL, Tanaka Y, Huang H, Gao J, and others. 2001. Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease. Nat Med7:1144–1150.
11.
Clayton DF, George JM. 1998. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci21:249–254.
12.
Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopaminealphasynuclein adduct. Science294:1346–9.
13.
Cookson MR. 2003. Parkin’s substrates and the pathways leading to neuronal damage. Neuromolecular Med3:1–13.
14.
Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, Abbas N, and others. 2003. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet12:517–526.
15.
Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, and others. 2002. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A99:14524–9.
16.
Davidson WS, Jonas A, Clayton DF, George JM. 1998. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem273:9443–9.
17.
Di Monte DA. 2003. The environment and Parkinson’s disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol2:531–538.
18.
Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, Bhatnagar A, and others. 2003. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem278:43628–35.
19.
Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. 2003. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A100:4078–4083.
20.
Gwinn-Hardy K. 2002. Genetics of parkinsonism. Mov Disord17:645–656.
21.
Hashimoto M, Hsu LJ, Rockenstein E, Takenouchi T, Mallory M, Masliah E. 2002. Alpha-synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signaling pathway in neuronal cells. J Biol Chem277:11465–72.
22.
Hashimoto M, Takenouchi T, Rockenstein E, Masliah E. 2003. Alphasynuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson’s disease. J Neurochem85:1468–1479.
23.
Ichimura T, Isobe T, Okuyama T, Takahashi N, Araki K, Kuwano R, and others. 1988. Molecular cloning of cDNA coding for brainspecific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc Natl Acad Sci U S A85:7084–8.
24.
Impey S, Fong AL, Wang Y, Cardinaux JR, Fass DM, Obrietan K, and others. 2002. Phosphorylation of CBP mediates transcriptional activation by neural activity and CaM kinase IV. Neuron34:235–244.
25.
Irizarry MC, Kim TW, McNamara M, Tanzi RE, George JM, Clayton DF, and others. 1996. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol55:889–895.
26.
Itier JM, Ibanez P, Mena MA, Abbas N, Cohen-Salmon C, Bohme GA, and others. 2003. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet12:2277–2291.
27.
Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, and others. 1995. The precursor protein of non-A beta component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron14:467–475.
28.
Iwata A, Maruyama M, Kanazawa I, Nukina N. 2001. Alpha-synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem276:45320–9.
29.
Jensen PH, Nielsen MS, Jakes R, Dotti CG, Goedert M. 1998. Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson’s disease mutation. J Biol Chem273:26292–4.
30.
Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ, and others. 2002. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain125:2248–2256.
31.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, and others. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature392:605–608.
32.
Lee FJ, Liu F, Pristupa ZB, Niznik HB. 2001. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J15:916–926.
33.
Lehmensiek V, Tan EM, Schwarz J, Storch A. 2002. Expression of mutant alpha-synucleins enhances dopamine transporter-mediated MPP+ toxicity in vitro. Neuroreport13:1279–1283.
34.
Lotharius J, Barg S, Wiekop P, Lundberg C, Raymon HK, Brundin P. 2002. Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. J Biol Chem277: 38884–94.
35.
Lotharius J, Brundin P. 2002. Pathogenesis of Parkinson’s disease: dopamine, vesicles and alpha-synuclein. Nat Rev Neurosci3:932–942.
36.
McLean PJ, Ribich S, Hyman BT. 2000. Subcellular localization of alpha-synuclein in primary neuronal cultures: effect of missense mutations. J Neural Transm Suppl:53–63.
37.
Miller DW, Ahmad R, Hague S, Baptista MJ, Canet-Aviles R, McLendon C, and others. 2003. L166P mutant DJ-1, causative for recessive Parkinson’s disease, is degraded through the ubiquitinproteasome system. J Biol Chem278:36588–95.
38.
Murphy DD, Rueter SM, Trojanowski JQ, Lee VM. 2000. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci20:3214–3220.
39.
Peng XR, Jia Z, Zhang Y, Ware J, Trimble WS. 2002. The septin CDCrel-1 is dispensable for normal development and neurotransmitter release. Mol Cell Biol22:378–387.
40.
Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. 2002. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci22:3090–9.
41.
Petrucelli L, O’Farrell C, Lockhart PJ, Baptista M, Kehoe K, Vink L, and others. 2002. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron36:1007–1019.
42.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, and others. 1997. Mutation in the •-synuclein gene identified in families with Parkinson’s disease. Science276:2045–7.
43.
Scherzer CR, Jensen RV, Gullans SR, Feany MB. 2003. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson’s disease. Hum Mol Genet12:2457–2466.
44.
Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, and others. 2002. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. Faseb J16:1826–8.
45.
Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, Selkoe DJ. 2003. The formation of highly soluble oligomers of alphasynuclein is regulated by fatty acids and enhanced in Parkinson’s disease. Neuron37:583–595.
46.
Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, and others. 2001. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson’s disease. Science293:263–269.
47.
Singleton AB, Farrer M, Johnson J, Singleton A, Hagu, S, Kachergus J, and others. 2003. •-synuclein locus triplication causes Parkinson’s disease. Science301:841-841.
48.
Snyder H, Mensah K, Theisler C, Lee J, Matouschek A, Wolozin B. 2003. Aggregated and monomeric alpha-synuclein bind to the S6’ proteasomal protein and inhibit proteasomal function. J Biol Chem278:11753–9.
49.
Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr. 2000. Expression of alpha-synuclein, parkin, and ubiquitin carboxyterminalhydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol47:201–210.
50.
Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, Abeliovich A. 2003. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron37:735–749.
51.
Stokes AH, Hastings TG, Vrana KE. 1999. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res55:659–665.
52.
Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, and others. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet10:919–926.
53.
Taylor JP, Hardy J, Fischbeck KH. 2002. Toxic proteins in neurodegenerative disease. Science296:1991–5.
54.
Tsai YC, Fishman PS, Thakor NV, Oyler GA. 2003. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J Biol Chem278:22044–55.
55.
Uversky VN. 2003. A protein-chameleon: conformational plasticity of alpha-synuclein, a disordered protein involved in neurodegenerative disorders. J Biomol Struct Dyn21:211–234.
56.
Volles MJ, Lansbury PT Jr. 2003. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson’s disease. Biochemistry42:7871–8.
57.
Wersinger C, Prou D, Vernier P, Sidhu A. 2003. Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. Faseb J17:2151–3.
58.
Wersinger C, Sidhu A. 2003. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci Lett340:189–192.
59.
Xu J, Kao SY, Lee FJS, Song W, Jin LW, Yankner BA. 2002. Dopamine-dependent neurotoxicity of •-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med8:600–606.
60.
Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. 2003. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron37:911–924.
61.
Zhang Y, Gao J, Chung KK, Huang H, Dawson VL, Dawson TM. 2000. Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. Proc Natl Acad Sci U S A97:13354–9.
